NASDAQ:RCKT
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$190.5M, and the diluted share count rose 17.2%.Summary generated from Rocket Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−60.3%
Debt / equityn/a
Free cash flow−$190.5M
FCF marginn/a
Share count change+17.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −167 | −224 | −260 | −273 | −232 |
| Net income | −169 | −222 | −246 | −259 | −223 |
| Free cash flow | −129 | −187 | −211 | −216 | −190 |
Recent filings
- 8-KEntry into a material agreement
Oct 6, 2026 - 4Insider transaction report
Sep 15, 2026 - 8-KRegulation FD disclosure
Sep 15, 2026 - 8-KDirector or officer change
Aug 27, 2026 - 4Insider transaction report
Aug 20, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KRegulation FD disclosure
Aug 3, 2026